Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Within-subject Variability of Insulin Detemir in Healthy Volunteers
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01497535
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01497587
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT01497561
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Graz, Germany
Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01497574
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT01497600
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT01490099
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 598
- Registration Number
- NCT01486940
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Falun, Sweden
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT01486966
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime
- Conditions
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2134
- Registration Number
- NCT01487421
Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis
- Conditions
- Interventions
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 19
- Registration Number
- NCT01461616
- Locations
- 🇩🇰
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.